Abstract:A series of novel substituted 5-phenyl methyl (Z) -2-(1-amino-2-((1,3,4-oxadiazol-2-yl)thio)ethylidene)hydrazine-1-carboxylate scaffolds 4(a-m) have been synthesized to assess their potential as anti-inflammatory and anticancer agents. The structures of the synthesized derivatives were established by employing 1 H- NMR, 13 C- NMR, and LC-MS analysis. In particular, thirteen derivatives were evaluated for their in vivo anti-inflammatory activity by making use of carrageenan-induced paw edema in SD rats and in vitro anticancer activity towards the BT474 female breast cancer cell line. Among the tested derivatives, Compound 4f emerged as a key lead and showed significant inhibition in paw edema volume in vivo (81%), and compound 4e exhibited interesting ability to inhibit cellular proliferation in vitro (IC 50 =3.78 μM for BT474) compared to Doxorubicin (IC 50 = 6.795 μM). Based on the structure-activity relationship, the presence of electron-donating substituents along with oxadiazole nucleus seems favorable for biological activities. A docking study was performed to understand the molecular interactions of the synthesized compounds which revealed that the compounds perfectly docked into the active sites of the protein.

1,3,4-Oxadiazole Derivatives As Potential Antitumor Agents: Discovery, Optimization and Biological Activity Valuation

Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel 1,3,4-Oxadiazole Derivatives Possessing Benzotriazole Moiety As FAK Inhibitors with Anticancer Activity.

Synthesis and biological activity of novel 1,3,4-oxadiazole derivatives containing a pyrazole moiety

Synthesis, Biological Evaluation and Molecular Docking Studies of 1,3,4-Thiadiazole Derivatives Containing 1,4-Benzodioxan As Potential Antitumor Agents

Synthesis, Biological Evaluation, and Molecular Docking Studies of 1,3,4-Thiadiazol-2-amide Derivatives As Novel Anticancer Agents

Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents.

Oxazole: A Promising Building Block for the Development of Potent Antitumor Agents.

Synthesis, Molecular Modeling, and Biological Evaluation of Quinazoline Derivatives Containing the 1,3,4-Oxadiazole Scaffold As Novel Inhibitors of VEGFR2

Synthesis, Molecular Modeling and Biological Evaluation of 2-Aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3h)-thione Quinolone Derivatives As Novel Anticancer Agent

Synthesis, Biological Evaluation, and Molecular Docking Studies of 2-Chloropyridine Derivatives Possessing 1,3,4-Oxadiazole Moiety As Potential Antitumor Agents

Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel 2-Styryl-5-nitroimidazole Derivatives Containing 1,4-Benzodioxan Moiety As FAK Inhibitors with Anticancer Activity.

Synthesis of Some New 1,3,4-Oxadiazole Derivatives and Evaluation of Their Anticancer Activity

Synthesis, Molecular Modeling, and Biological Evaluation of 1,2,4-Triazole Derivatives Containing Pyridine As Potential Anti-Tumor Agents

Synthesis and evaluation of biological and antitumor activities of 5,7-dimethyl- oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives as novel inhibitors of FGFR1.

Novel 1,3,4-oxadiazole-2- thiol derivatives: Unlocking the therapeutic potential as anti-inflammatory and anticancer agents

Novel 5-Methyl-2,4-disubstitued-oxazole Derivatives: Synthesis and Anticancer Activity

1,3,4-Oxadiazole Derivatives As Potential Biological Agents

Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors.

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Dithiocarbamate Moiety As Novel FAK Inhibitors with Antitumor and Anti-Angiogenesis Activities.

Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone Derivatives

Synthesis and Antitumor Activity of 1,3,4-Oxadiazole Possessing 1,4-Benzodioxan Moiety As a Novel Class of Potent Methionine Aminopeptidase Type II Inhibitors